Cerecor Inc. (CERC) Scheduled to Post Earnings on Monday
Cerecor (NASDAQ:CERC) last posted its quarterly earnings results on Tuesday, May 9th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.18. The business had revenue of $0.38 million during the quarter. Cerecor had a negative net margin of 864.87% and a negative return on equity of 896.66%. On average, analysts expect Cerecor to post $-0.97 EPS for the current fiscal year and $-0.87 EPS for the next fiscal year.
Shares of Cerecor Inc. (NASDAQ CERC) opened at 0.616 on Monday. The firm has a 50-day moving average of $0.71 and a 200 day moving average of $0.69. Cerecor Inc. has a 1-year low of $0.34 and a 1-year high of $5.60. The company’s market capitalization is $8.67 million.
COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/08/07/cerecor-inc-cerc-scheduled-to-post-earnings-on-monday.html.
In other Cerecor news, Director Armistice Capital Master Fund acquired 72,672 shares of the company’s stock in a transaction on Friday, May 19th. The stock was acquired at an average cost of $0.63 per share, with a total value of $45,783.36. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 10.70% of the company’s stock.
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
Receive News & Ratings for Cerecor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.